Bristol-Myers Squibb decides against accelerated approval for Opdivo/Yervoy combo for lung cancer

PRINCETON, N.J. — Bristol-Myers Squibb has announced that it will not seek an accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer. 

 

The company said the announcement was “based on a review of data available at this time,” and noted that they would not provide additional details to “protect the integrity of ongoing registrational studies.”

 

The Food and Drug Administration approved the regimen of Opdivo and Yervoy as a treatment for metastatic melanoma in October 2015.